 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PHILADELPHIA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell...

Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference

Century Therapeutics (NASDAQ:IPSC Get Free Report) was downgraded by analysts at JPMorgan Chase & Co. from an overweight rating to a neutral rating in a note issued to investors on Monday, MarketBeat.com reports. They currently have a $5.00 price objective on the stock, down from their previous ...

Century Therapeutics (NASDAQ:IPSC) Stock Rating Lowered by JPMorgan Chase & Co.

Century Therapeutics (NASDAQ:IPSC  Get Free Report) was downgraded by analysts at JPMorgan Chase  Co. from an overweight rating to a neutral rating in a...

Century Therapeutics (NASDAQ:IPSC) Cut to Neutral at JPMorgan Chase & Co.

Genetic Technologies (NASDAQ:GENE Get Free Report) and Century Therapeutics (NASDAQ:IPSC Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, ...

Century Therapeutics (NASDAQ:IPSC) versus Genetic Technologies (NASDAQ:GENE) Financial Analysis

Century Therapeutics (NASDAQ:IPSC  Get Free Report) and Genetic Technologies (NASDAQ:GENE  Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, ...

Century Therapeutics (NASDAQ:IPSC) and Genetic Technologies (NASDAQ:GENE) Financial Contrast

Shares of Century Therapeutics, Inc. (NASDAQ:IPSC Get Free Report) have been given an average recommendation of Buy by the seven brokerages that are covering the company, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating. The average twelve-month price target among ...

Century Therapeutics, Inc. (NASDAQ:IPSC) Receives Average Rating of "Buy" from Brokerages

Century Therapeutics, Inc. (NASDAQ:IPSC Free Report) Stock analysts at Chardan Capital lifted their FY2023 earnings per share (EPS) estimates for shares of Century Therapeutics in a research note issued on Wednesday, August 9th. Chardan Capital analyst Y. Livshits now anticipates that the company ...

FY2023 EPS Estimates for Century Therapeutics, Inc. Boosted by Analyst (NASDAQ:IPSC)

Century Therapeutics, Inc. (NASDAQ:IPSC Free Report) Research analysts at Chardan Capital upped their FY2023 EPS estimates for shares of Century Therapeutics in a research note issued to investors on Wednesday, August 9th. Chardan Capital analyst Y. Livshits now anticipates that the company will ...

FY2023 EPS Estimates for Century Therapeutics, Inc. (NASDAQ:IPSC) Boosted by Chardan Capital

Century Therapeutics (NASDAQ:IPSC  Get Free Report) and Fennec Pharmaceuticals (NASDAQ:FENC  Get Free Report) are both small-cap medical companies, but which is the better investment...

Head-To-Head Analysis: Century Therapeutics (NASDAQ:IPSC) versus Fennec Pharmaceuticals (NASDAQ:FENC)

Century Therapeutics, Inc. (NASDAQ:IPSC  Free Report)  Stock analysts at William Blair raised their Q3 2023 earnings per share (EPS) estimates for Century Therapeutics in a report released on Wednesday, August 9th. William Blair analyst S. Corwin now expects that the company will earn...

Brokers Issue Forecasts for Century Therapeutics, Inc.'s Q3 2023 Earnings (NASDAQ:IPSC)

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It focuses on harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.

Watchers	249
52-Wk Low	$2.00
52-Wk High	$11.95

Market Cap	$120.73M
Volume (M)	41,644.00
52-Wk High	$11.95
52-Wk Low	$2.00

IPSC Century Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals